17-Jul-2026
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
Business Wire (Fri, 17-Jul 6:01 AM ET)
BeOne Medicines Ltd (6160) Receives a Buy from Macquarie
TipRanks (Tue, 14-Jul 8:25 PM ET)
BeOne Medicines Halts Early BGB-21447 Cancer Trial: What Investors Should Watch
TipRanks (Tue, 14-Jul 12:30 PM ET)
BeOne Medicines (ONC) Gets a Buy from Barclays
TipRanks (Tue, 14-Jul 4:37 AM ET)
Market Chameleon (Tue, 30-Jun 3:09 AM ET)
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
Business Wire (Tue, 30-Jun 6:00 AM ET)
Business Wire (Fri, 12-Jun 6:00 AM ET)
Business Wire (Thu, 11-Jun 7:24 AM ET)
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
Business Wire (Mon, 1-Jun 6:00 AM ET)
Business Wire (Fri, 29-May 6:00 AM ET)
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of July 17, 2026, ONC stock price declined to $312.02 with 403,706 million shares trading.
ONC has a beta of 0.80, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.05 to the broad based SPY ETF.
ONC has a market cap of $32.37 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $3.24 earnings per share. This beat revenue expectation by $72 million and exceeded earnings estimates by $2.45.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, BBH, CGIE.
ONC has underperformed the market in the last year with a return of +7.5%, while the SPY ETF gained +19.5%. In the last 3 month period, ONC fell short of the market, returning -3.7%, while SPY returned +4.9%. However, in the most recent 2 weeks ONC has outperformed the stock market by returning +4.8%, while SPY returned -0.2%.
ONC support price is $310.36 and resistance is $324.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.